Ieq Capital LLC Increases Position in Illumina, Inc. (NASDAQ:ILMN)

Ieq Capital LLC increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 181.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 28,507 shares of the life sciences company’s stock after acquiring an additional 18,371 shares during the period. Ieq Capital LLC’s holdings in Illumina were worth $3,809,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Empowered Funds LLC grew its position in Illumina by 1.7% in the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after acquiring an additional 66 shares in the last quarter. Caprock Group LLC grew its position in Illumina by 3.0% in the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after acquiring an additional 83 shares in the last quarter. Integrated Advisors Network LLC grew its position in Illumina by 2.0% in the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after acquiring an additional 90 shares in the last quarter. Stephens Inc. AR lifted its stake in Illumina by 1.4% in the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock worth $885,000 after purchasing an additional 90 shares during the last quarter. Finally, Moors & Cabot Inc. lifted its stake in Illumina by 1.7% in the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock worth $759,000 after purchasing an additional 95 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ILMN has been the subject of several recent research reports. Canaccord Genuity Group lowered their price target on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday, February 7th. Stephens boosted their price target on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Barclays downgraded shares of Illumina from an “equal weight” rating to an “underweight” rating and lowered their price target for the stock from $130.00 to $100.00 in a research note on Monday, February 10th. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. Finally, Guggenheim lowered their price target on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Illumina currently has an average rating of “Moderate Buy” and a consensus target price of $159.45.

Illumina Stock Performance

Shares of ILMN opened at $94.20 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a one year low of $93.50 and a one year high of $156.66. The company has a 50-day simple moving average of $127.98 and a two-hundred day simple moving average of $134.01. The firm has a market capitalization of $14.92 billion, a PE ratio of -12.27, a price-to-earnings-growth ratio of 1.70 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.